November 19, 2024

Phase 3 ARISE Trial of Parkinson Therapy Solengepras Begins Dosing

The global, placebo-controlled, 12-week study aims to enroll 330 participants and expects topline results in the first half of 2026.

November 19, 2024

Questions About Vision & Parkinson’s Disease – American Parkinson Disease Association

November 17, 2024

Combating Parkinson’s with rock climbing – CBS News

November 17, 2024

Science & Medicine: Exercise is medicine for people with Parkinson’s disease – Texas Public Radio

November 11, 2024

Column | Make this one lifestyle change to lower your Parkinson’s disease risk – The Washington Post